“People living with diabetes are benefiting from our Control-IQ technology across diverse populations and therapeutic backgrounds, which supports our mission to improve the lives of people living with ...

Tandem Diabetes Care, Inc. TNDM presented positive real-world data, showing immediate and continued benefits across a diverse group of people using the t:slim X2 insulin pump with the Control-IQ ...

Tandem Diabetes Care, Inc. TNDM recently presented data on real-world use of the t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology at the 14th International Conference on ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced publication of results from the Pediatric Artificial ...

The FDA approved its first automatic insulin dosing system designed to deliver correction boluses as well as adjust background insulin levels to help prevent bouts of high and low blood sugar in ...

Tandem Diabetes Care TNDM remained under pressure on Monday, after the company accounted for plans of a combined analysis of three trials of its Control-IQ technology. Tandem Diabetes Care’s margins ...

Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, announced real-world data confirming that use of the t:slim X2™ insulin pump with Control-IQ® ...

On Jun 1, 2020, we issued an updated research report on Tandem Diabetes Care, Inc. TNDM. The company's expansion initiatives in the global markets are a major positive. However, its heavy dependence ...

A new software system that will let people with diabetes customize their treatment and automatically adjust their insulin levels was just approved for use by the Food and Drug Administration. It will ...

Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, announced real-world data confirming that use of the t:slim X2 insulin pump with Control-IQ ...